BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35810270)

  • 1. Colposcopy non-attendance following an abnormal cervical cancer screening result: a prospective population-based cohort study.
    Liang LA; Zeissig SR; Schauberger G; Merzweiler S; Radde K; Fischbeck S; Ikenberg H; Blettner M; Klug SJ
    BMC Womens Health; 2022 Jul; 22(1):285. PubMed ID: 35810270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
    Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
    Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain.
    Ibáñez R; Moreno-Crespi J; Sardà M; Autonell J; Fibla M; Gutiérrez C; Lloveras B; Alejo M; Català I; Alameda F; Casas M; Bosch FX; de Sanjosé S
    BMC Infect Dis; 2012 Jan; 12():25. PubMed ID: 22280073
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of a high-risk human papillomavirus DNA test as the primary test in a cervical cancer screening programme: a population-based cohort study.
    Zorzi M; Del Mistro A; Farruggio A; de'Bartolomeis L; Frayle-Salamanca H; Baboci L; Bertazzo A; Cocco P; Fedato C; Gennaro M; Marchi N; Penon MG; Cogo C; Ferro A
    BJOG; 2013 Sep; 120(10):1260-7; discussion 1267-8. PubMed ID: 23786222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Attendance at early recall and colposcopy in routine cervical screening with human papillomavirus testing.
    Green LI; Mathews CS; Waller J; Kitchener H; Rebolj M;
    Int J Cancer; 2021 Apr; 148(8):1850-1857. PubMed ID: 33070318
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of two strategies to follow-up ASC-US and LSIL screening results in The Netherlands using repeat cytology with or without additional hrHPV testing: a retrospective cohort study.
    Siebers AG; Arbyn M; Melchers WJ; van Kemenade FJ; Vedder JE; van der Linden H; van Ballegooijen M; Bekkers RL; Bulten J
    Cancer Causes Control; 2014 Sep; 25(9):1141-9. PubMed ID: 24935226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The IMproving Primary Screening And Colposcopy Triage trial: human papillomavirus, cervical cytology, and histopathologic results from the baseline and 1-year follow-up phase.
    Safaeian M; Wright TC; Stoler MH; Ranger-Moore J; Rehm S; Aslam S; Fang Q; Volkir P; Ridder R
    Am J Obstet Gynecol; 2021 Sep; 225(3):278.e1-278.e16. PubMed ID: 33852886
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary HPV screening for cervical cancer: Results after two screening rounds in a regional screening program in Finland.
    Veijalainen O; Kares S; Kotaniemi-Talonen L; Kujala P; Vuento R; Luukkaala T; Kholová I; Mäenpää J
    Acta Obstet Gynecol Scand; 2021 Mar; 100(3):403-409. PubMed ID: 33037625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Impact of Triage for Atypical Squamous Cells of Undetermined Significance with Human Papillomavirus Testing in Cervical Cancer Screening in Japan.
    Fujiwara H; Suzuki M; Morisawa H; Sayama M; Kimura K
    Asian Pac J Cancer Prev; 2019 Jan; 20(1):81-85. PubMed ID: 30678384
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety of screening with Human papillomavirus testing for cervical cancer at three-year intervals in a high-risk population: experience from the LAMS study.
    Derchain SF; Sarian LO; Naud P; Roteli-Martins C; Longatto-Filho A; Tatti S; Branca M; Erzen M; Serpa-Hammes L; Matos J; Gontijo RC; Bragança JF; Lima TP; Maeda MY; Lörincz A; Dores GB; Costa S; Syrjänen S; Syrjänen K
    J Med Screen; 2008; 15(2):97-104. PubMed ID: 18573778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Provider management of equivocal cervical cancer screening results among underserved women, 2009-2011: follow-up of atypical squamous cells of undetermined significance.
    Watson M; Benard V; Lin L; Rockwell T; Royalty J
    Cancer Causes Control; 2015 May; 26(5):759-64. PubMed ID: 25794897
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cervical Precancer and Cancer Risk by Human Papillomavirus Status and Cytologic Interpretation: Implications for Risk-Based Management.
    Castle PE; Aslam S; Behrens C
    Cancer Epidemiol Biomarkers Prev; 2016 Dec; 25(12):1595-1599. PubMed ID: 27587789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Introduction of liquid-based cytology and human papillomavirus testing in cervical cancer screening in Luxembourg.
    Latsuzbaia A; Hebette G; Fischer M; Arbyn M; Weyers S; Vielh P; Schmitt F; Mossong J
    Diagn Cytopathol; 2017 May; 45(5):384-390. PubMed ID: 28247516
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of alternative triage strategies for atypical squamous cells of undetermined significance.
    Kim JJ; Wright TC; Goldie SJ
    JAMA; 2002 May; 287(18):2382-90. PubMed ID: 11988059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colposcopy Requirement of Papanicolaou Smear after Atypical Squamous Cells of Undetermined Significance (ASC-US) by Follow-up Protocol in an Urban Gynaecology Clinic, a Retrospective Study in Thailand.
    Perksanusak T; Sananpanichkul P; Chirdchim W; Bhamarapravatana K; Suwannarurk K
    Asian Pac J Cancer Prev; 2015; 16(12):4977-80. PubMed ID: 26163625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The reliability of high-risk human papillomavirus detection by Aptima HPV assay in women with ASC-US cytology.
    Castle PE; Reid J; Dockter J; Getman D
    J Clin Virol; 2015 Aug; 69():52-5. PubMed ID: 26209379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liquid-based cytology and human papillomavirus testing: a pooled analysis using the data from 13 population-based cervical cancer screening studies from China.
    Pan QJ; Hu SY; Guo HQ; Zhang WH; Zhang X; Chen W; Cao J; Jiang Y; Zhao FH; Qiao YL
    Gynecol Oncol; 2014 May; 133(2):172-9. PubMed ID: 24631450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Results of delayed triage by HPV testing and cytology in the Norwegian Cervical Cancer Screening Programme.
    Haldorsen T; Skare GB; Ursin G; Bjørge T
    Acta Oncol; 2015 Feb; 54(2):200-9. PubMed ID: 24957553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.